Please login to the form below

Not currently logged in
Email:
Password:

Eisai launches epilepsy treatment Zebinix in France

Will receive full reimbursement from French healthcare authorities three years after European approval

Japanese pharmaceutical company Eisai has launched its epilepsy drug Zebinix (eslicarbazepine acetate) in France three years after it was approved for use in Europe.

The drug, which will receive full reimbursement from the French health authorities, is a novel once-daily treatment indicated as an adjunctive therapy for adults with partial-onset seizures.

It is already available in several European countries, including the UK, Germany, Sweden, Spain and Greece.

In Spain, the drug is co-promoted by Eisal and Bial – the original developers of the product.

Bial has exclusive rights to promote the drug in Cyprus, Malta, Albania and Portugal as part of the 2009 deal between the two companies.

Zebinix is intended to help the third of patients with epilepsy who still experience seizures after initial treatment.

These seizures can lead to poor health, reduced likelihood of employment and an increased risk of psychological comorbidities according to Arnaud Biraben, a consultant neurologist at Pontchaillou Hospital in France.

Michaël Perrin, director of Eisai's epilepsy business, said: “The launch of Zebinix is a positive step for patients in France who do not achieve adequate seizure control.”

“Eisai is working with the regional health authorities to ensure the treatment is available as soon as possible to patients that require it the most”.

Epilepsy is thought to affect more than 500,000 people in France, according to Eisai, costing the health services more €3.5bn annually.

Zebinix has been shown to significantly reduce seizure frequency compared to placebo in phase III clinical trials, while long-term safety and continuation of its effect was demonstrated in one-year open-label extensions of these studies.

It is developed to target the sodium ion channel, which can lead to seizures when in an overactive state of neuronal firing.

Zebinix stops an inactive sodium ion channel returning to its active state, reducing the risk of seizures.

19th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...